Back to Search
Start Over
Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia.
- Source :
-
Vascular medicine (London, England) [Vasc Med] 2015 Oct; Vol. 20 (5), pp. 447-53. Date of Electronic Publication: 2015 May 11. - Publication Year :
- 2015
-
Abstract
- Fibromuscular dysplasia (FMD), a non-inflammatory arterial disease, may lead to renovascular hypertension (HTN) and cerebrovascular disease. Little is known about medication use in FMD. Clinical features and medication use were reviewed in a national FMD registry (12 US sites). Medication usage was assessed in raw and adjusted analyses. Covariates included demographic characteristics, co-morbid conditions and vascular bed involvement. A total of 874 subjects (93.6% female) were included in the analysis. Mean age was 55.6±13.1 years, 74.5% had HTN, 25.4% had a history of transient ischemic attack or stroke, and 7.5% had a history of coronary artery disease (CAD). Renal and cerebrovascular arteries were affected in 70.4% and 74.7%, respectively. Anti-platelet agents were administered to 72.9% of patients. In multivariate analyses, factors associated with a greater likelihood of anti-platelet agent use were older age (OR=1.02 per year, p=0.005), CAD (OR=3.76, p=0.015), cerebrovascular artery FMD involvement in isolation (OR=2.31, p<0.0001) or a history of previous intervention for FMD (OR=1.52, p=0.036). A greater number of anti-HTN medications was evident in isolated renal versus isolated cerebrovascular FMD patients. Factors associated with a greater number of anti-HTN medications were older age (OR=1.03 per year, p<0.0001), history of HTN (OR=24.04, p<0.0001), history of CAD (OR=2.71, p=0.0008) and a history of a previous therapeutic procedure (OR=1.72, p=0.001). In conclusion, in FMD, medication use varies based on vascular bed involvement. Isolated renal FMD patients receive more anti-HTN agents and there is greater anti-platelet agent use among patients with cerebrovascular FMD. Further studies correlating medication use in FMD with clinically meaningful patient outcomes are necessary.<br /> (© The Author(s) 2015.)
- Subjects :
- Adult
Aged
Female
Fibromuscular Dysplasia complications
Humans
Hypertension, Renovascular
Male
Middle Aged
Registries statistics & numerical data
Renal Artery drug effects
United States
Antihypertensive Agents therapeutic use
Blood Platelets drug effects
Fibromuscular Dysplasia drug therapy
Platelet Aggregation Inhibitors therapeutic use
Renal Artery Obstruction drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1477-0377
- Volume :
- 20
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Vascular medicine (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 25964292
- Full Text :
- https://doi.org/10.1177/1358863X15584982